Latest operating income for ACRX: $-15M.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026
Acelrx Pharmaceuticals (ACRX) currently reports a operating income of $-15M as of March 2026. That compares with $-19M in the prior-year period — up 24.0% year over year. Use the charts on this page to explore Acelrx Pharmaceuticals's operating income history and peer comparisons.
Acelrx Pharmaceuticals's operating income increased from $-19M to $-15M — a 24.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Acelrx Pharmaceuticals reported $-15M in operating income as of March 2026. That compares with $-19M in the prior-year period — up 24.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acelrx Pharmaceuticals, and consider following ACRX for alerts when major investors trade the stock.
Acelrx Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACRX with unrelated industries.